Icure Pharmaceutical Incorporation Logo

Icure Pharmaceutical Incorporation

Develops transdermal patches for dementia/Parkinson's and offers cosmetic ODM/OBM services.

175250 | KO

Overview

Corporate Details

ISIN(s):
KR7175250000
LEI:
Country:
South Korea
Address:
서울특별시 강남구 봉은사로104길 10 7층, 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Icure Pharmaceutical Incorporation is a biopharmaceutical company specializing in the research, development, and commercialization of products based on its Transdermal Drug Delivery System (TDDS) technology. Established in 2000, the company develops innovative new drugs, including transdermal patches for dementia and Parkinson's disease. Icure also operates a cosmeceutical business, leveraging its pharmaceutical expertise to offer Original Design Manufacturing (ODM) and Original Brand Manufacturing (OBM) services for cosmetics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상 결정)
Korean 4.9 KB
2025-09-17 00:00
Delisting Announcement
주권매매거래정지기간변경 (상장적격성 실질심사 대상 결정)
Korean 4.7 KB
2025-09-16 00:00
Capital/Financing Update
주요사항보고서(자기전환사채만기전취득결정)
Korean 14.7 KB
2025-08-27 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-08-22 00:00
Capital/Financing Update
주요사항보고서(자기전환사채만기전취득결정)
Korean 14.7 KB
2025-08-22 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 85.9 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.6 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-05 00:00
Legal Proceedings Report
횡령ㆍ배임혐의발생
Korean 8.7 KB
2025-08-05 00:00
Delisting Announcement
주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))
Korean 4.6 KB
2025-08-05 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 관련 안내)
Korean 2.7 KB
2025-08-05 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내)
Korean 3.0 KB
2025-07-16 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 79.1 KB
2025-07-10 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 66.8 KB
2025-06-30 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.0 KB

Automate Your Workflow. Get a real-time feed of all Icure Pharmaceutical Incorporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Icure Pharmaceutical Incorporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Icure Pharmaceutical Incorporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.